What is the STRIDE‑RCT trial?
More than 20,000 patients across 200 GP practices will be offered a cutting‑edge blood test as part of the STRIDE‑RCT study. The programme aims to evaluate how well these tests perform in everyday practice, helping doctors decide whether a patient needs further cancer investigation or can be reassured that the disease is absent. Scientists explain that the assays detect molecular signals in the blood that indicate the presence of cancer, allowing early referral or safe dismissal. Over an 18‑to‑24‑month period the trial will generate the evidence needed to consider a national rollout.
How the four blood tests work
The trial involves four distinct diagnostics. Proteotype’s Enlighten test measures patterns of circulating amino‑acid biomarkers and, with AI, looks for signs of breast, bowel, lung or prostate cancer, guiding GPs on who should be referred for further scans. Pinpoint AI combines faint cancer signals from the bloodstream into a single, stronger result, aiming to reduce unnecessary referrals. Natera’s Signatera assay detects circulating tumour DNA fragments shed by existing tumours, currently used to monitor cancer recurrence. Mercy BioAnalytics’ Halo test analyses single extracellular vesicles that circulate in high numbers even in early‑stage disease. Together they assess 32 biomarkers simultaneously, categorising risk as green (low), amber (average) or red (high) to direct the next steps.
Who is being invited to take part?
Eligible participants are adults aged 45 and over who visit their GP with abdominal symptoms such as persistent bloating, discomfort or changes in bowel habits. The invitation offers them the chance to undergo one of the four tests as an initial step in the diagnostic pathway. This focus on abdominal complaints targets cancers that are often hard to spot early because their signs can be mistaken for less serious conditions.
What the experts say
Health Minister James Frith described the initiative as a world‑first trial for earlier detection of abdominal cancers, which are notoriously difficult to diagnose. He noted that many patients present with vague symptoms that are frequently misinterpreted, and the blood tests could provide the clarity needed to move patients swiftly onto the right pathway or give them peace of mind. Health Secretary Yvette Cooper emphasised that earlier diagnosis saves lives and aligns with the National Cancer Plan’s goal of faster, more effective care. Professor Peter Johnson, NHS national clinical director for cancer, said the trial marks the beginning of a revolution in how cancer is identified, while Michelle Mitchell of Cancer Research UK highlighted the long‑standing need for GPs to have better tools for triaging suspicious cases.
Why it Matters
Early detection of cancer dramatically improves treatment outcomes and survival rates, and this trial could transform how the NHS approaches suspected cancer referrals. By identifying low‑risk patients quickly, the tests could spare thousands from invasive investigations, while flagging high‑risk cases for urgent attention, thereby easing pressure on overstretched hospital services. If the evidence proves successful, the simple blood test could become a routine part of primary‑care assessment, offering a scalable solution to the longstanding challenge of early cancer diagnosis.
